Klajdi, our CEO at Luminary Group, will be attending the World Drug Safety Congress Europe from 09-10 October. If you'd like to grab 5-10 minutes with Klajdi to discuss potential collaborations or share insights, feel free to reach out and connect. It’s a great opportunity to explore new ideas and strengthen relationships in the industry. Luminary Group has positioned itself as a leader in the consulting space, specializing in placing top executives and offering tailored commercial, operational, and outsourcing solutions for pharmaceutical companies in niche areas such as pharmacovigilance and regulatory affairs across Europe, the USA, and APAC. We are excited to meet with our industry partners and peers at the event. Looking forward to seeing you all there! #WDSC #pharmacovigilance #pharma #regulatory #compliance #pv #lifescience #healthcare #consulting #amsterdam #netherlands #worlddrugsafetyeurope #worlddrugsafety
About us
Luminary Group is a international business consultancy focused on the life sciences and pharmaceutical sectors. Headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, we deliver comprehensive services in three key areas. Luminary Executive: Specializing in C-suite to Director-level appointments, we identify top talent for positions including Chairman, Board members, CEO, CCO, COO, AVP to Director level. Luminary Staffing: We provide both temporary and permanent staffing solutions tailored to meet the commercial, project management, medical, biometrics, software and operational needs of our clients. Luminary Consulting: Offering high-quality services in medical writing, regulatory affairs, quality assurance, pharmacovigilance, and data science for the medical and pharmaceutical industries. We also provide strategic partnerships to accelerate growth through Recruitment Process Outsourcing (RPO) and Functional Service Provider (FSP) services. Lastly, our advisory services assist in data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe, and provide guidance for business collaborations with biotechnology firms and navigating mergers and acquisitions. Our expertise includes Real World Evidence (RWE), eClinical solutions, Artificial Intelligence (AI), Biotechnology, Consulting, and Medical Devices. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from corporate giants to innovative start-ups. For more information, please visit our website: www.luminarygroup.co.uk.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
-
4th St N, STE 300
7901
St. Petersburg, FL , 33702, US
Employees at Luminary Group
Updates
-
𝗦𝘂𝗽𝗲𝗿𝗻𝘂𝘀’ 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗱𝗿𝘂𝗴 𝘀𝗵𝗼𝘄𝘀 ‘𝗿𝗮𝗽𝗶𝗱’ 𝗼𝗻𝘀𝗲𝘁 𝗶𝗻 𝗺𝗶𝗱-𝘀𝘁𝗮𝗴𝗲 𝘁𝗲𝘀𝘁 Supernus Pharmaceuticals, Inc. mTORC1 activator has cleared a small trial in patients with major depressive disorder, potentially bringing the biotech one step closer to offering a … https://lnkd.in/ddDehqhn
-
𝗣𝗳𝗶𝘇𝗲𝗿’𝘀 𝗥𝗦𝗩 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗵𝗮𝘀 𝟵𝟬% 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝘀𝗲𝘃𝗲𝗿𝗲 𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 Pfizer RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the company said, underscoring its potential benefits as … https://lnkd.in/daGFPEHZ
Pfizer’s RSV vaccine has 90% efficacy against severe respiratory disease
endpts.com
-
𝗧𝗲𝗿𝗿𝗮𝘆 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟮𝟬𝗠 𝗳𝗼𝗿 𝗶𝘁𝘀 𝗔𝗜 𝘄𝗮𝘆𝘀 𝗼𝗳 𝗱𝗲𝘀𝗶𝗴𝗻𝗶𝗻𝗴 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 Terray Therapeutics has raised a $120 million Series B round, aiming to get its first drug candidate into the clinic while advancing in its AI …Jacob Berlin, Eli Berlin https://lnkd.in/gtieiu2P
Exclusive: Terray raises $120M for its AI ways of designing molecules
endpts.com
-
𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗗𝗠𝗢 𝗯𝗿𝗼𝗮𝗱𝗲𝗻𝘀 𝗖𝗚𝗧 𝗳𝗼𝗼𝘁𝗽𝗿𝗶𝗻𝘁 𝘄𝗶𝘁𝗵 𝗻𝗲𝘄 $𝟭𝟰𝟱𝗠 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝘆 CDMO OMNIABIOS S.R.L. on Thursday opened a commercial-stage cell manufacturing facility that has AI capabilities worth around CAD $200 million ($145 million) in its hometown of … https://lnkd.in/dXmjhH4S
Canadian CDMO broadens CGT footprint with new $145M facility
endpts.com
-
𝗦𝗮𝗻𝗼𝗳𝗶 𝗶𝗻𝘃𝗲𝘀𝘁𝘀 𝗶𝗻 𝗻𝗲𝘄 𝗿𝗮𝗱𝗶𝗼𝗹𝗶𝗴𝗮𝗻𝗱 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗢𝗿𝗮𝗻𝗼 𝗠𝗲𝗱, 𝗯𝘂𝘆𝗶𝗻𝗴 𝟭𝟲% 𝘀𝘁𝗮𝗸𝗲 𝗳𝗼𝗿 €𝟯𝟬𝟬𝗠 A month after making a foray into the bustling radioligand field, Sanofi is further allying itself with Orano Med Med, paying €300 million … https://lnkd.in/duGiVtjT
Sanofi invests in new radioligand partner Orano Med, buying 16% stake for €300M
endpts.com
-
𝗟𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗞𝗱𝗧 𝗩𝗲𝗻𝘁𝘂𝗿𝗲𝘀 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟬𝟬𝗠 𝗳𝘂𝗻𝗱 𝘁𝗼 𝗯𝗮𝗰𝗸 𝗻𝗲𝘄 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 Life sciences Vc shOp KdT Ventures disclosed its $100 million fourth fund on Wednesday morning, just over two years after announcing an $80 million fund … https://lnkd.in/dnCZuXqE
Life sciences investor KdT Ventures raises $100M fund to back new startups
endpts.com
-
𝗝𝗮𝘇𝘇 𝗿𝗲𝗽𝗼𝗿𝘁𝘀 𝗣𝗵𝗮𝘀𝗲 𝟯 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗳𝗼𝗿 𝗭𝗲𝗽𝘇𝗲𝗹𝗰𝗮 𝗶𝗻 𝗳𝗶𝗿𝘀𝘁-𝗹𝗶𝗻𝗲 𝗺𝗮𝗶𝗻𝘁𝗲𝗻𝗮𝗻𝗰𝗲 𝗳𝗼𝗿 𝘀𝗺𝗮𝗹𝗹 𝗰𝗲𝗹𝗹 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 Jazz Pharmaceuticals announced Tuesday that adding its small cell lung cancer drug ZEPZELCA® (lurbinectedin) HCP to a maintenance treatment regimen for extensive-stage small … https://lnkd.in/dn5fSGdw
Jazz reports Phase 3 success for Zepzelca in first-line maintenance for small cell lung cancer
endpts.com
-
𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 𝗿𝗲𝘃𝗲𝗮𝗹𝘀 £𝟮𝟳𝟵𝗠 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗨𝗞 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗻𝗲𝘄 𝗴𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝗱𝗲𝗮𝗹 Eli Lilly and Company plans to invest £279 million ($364 million) in the UK as part of a new government partnership in which the drugmaker will bring … https://lnkd.in/d9EbxtcQ
Eli Lilly reveals £279M investment in the UK through new government deal
endpts.com
-
𝗣𝗳𝗶𝘇𝗲𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝘄𝗶𝘁𝗵 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗴𝗹𝘂𝗲 𝘀𝘁𝗮𝗿𝘁𝘂𝗽 𝗧𝗿𝗶𝗮𝗻𝗮 𝗶𝗻 $𝟰𝟵𝗠 𝘂𝗽𝗳𝗿𝗼𝗻𝘁 𝗱𝗲𝗮𝗹 Pfizer is deepening its investment in protein degraders through a new partnership with TRIANA Biomedicines a startup working in the trendy field of molecular glues https://lnkd.in/dcnfYZyC
Pfizer partners with molecular glue startup Triana in $49M upfront deal
endpts.com